ReViral Ltd   Report issue

For profit Phase 1 Phase 2
Founded: Stevenage United Kingdom (2011)
Status: Acquired by Pfizer (2022)

Organization Overview

First Clinical Trial
2017
NCT03258502
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

ReViral Ltd

Active Ingredients

Drugs in Phase 2 Trials (1)

RV521 (5 trials)

Drugs in Phase 1 Trials (4)

itraconazole (sporanox) (1 trial)

midazolam (versed) (1 trial)

rifampin (1 trial)

verapamil (calan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 2)

Infections (Phase 2)

Respiratory Syncytial Virus Infections (Phase 2)

Respiratory Tract Infections (Phase 2)

Virus Diseases (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 5